Showing posts with label CYP2D6. Show all posts
Showing posts with label CYP2D6. Show all posts
Tuesday, March 06, 2012
JNCI Commentary (open access): CYP2D6 Genotype as a Marker for Benefit of Adjuvant Tamoxifen in Postmenopausal Women: Lessons Learned
Blogger's Note: see extensive references including current papers regarding this issue
"Since 2003, there has been considerable interest and a good degree of credence given to the role of cytochrome P450 2D6 (CYP2D6) genotyping to predict tamoxifen benefit in adjuvant therapy (1–5). This construct was based on the fact that a variety of CYP2D6 polymorphisms lead to reduced CYP2D6 enzyme activity and hence result in lower plasma concentrations of endoxifen, a clinically active metabolite of tamoxifen.....
"In the end, it is crucial to obtain data from randomized trials for clinical demonstration of associations between biomarkers and disease outcomes. To advance breast cancer therapy, laboratory observations that raise hypotheses must be at the very core of what we do; however, it is only after independent validation that they can begin guide clinical practice."
add your opinions
breast cancer biomarkers
,
CYP2D6
,
genotype
,
Tamoxifen
Subscribe to:
Posts
(
Atom
)